Eton Pharmaceuticals Submits FDA Prior Approval Supplement For Its New Formulation Of KHINDIVI Oral Solution
Eton Pharmaceuticals Inc ETON
$46.42
▼ -5.32%
($-2.61)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$49.09
Prev Close
$49.03
Day Range
$46.01 – $49.09
52W Range
$13.78 – $50.18
Market Cap
$1.27B
Beta
0.86
EPS (TTM)
$-0.06
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-11-09 |
| Shares Out. | 27,390,000 |
| Website | etonpharma.com/ ↗ |
| Phone | 18004831140 |
| Employees | 44 |
| Revenue | $24.3M |
| Gross Profit | $14.7M |
| Net Income | $1.6M |
| Free Cash Flow | $15.4M |
| Total Assets | $97.7M |
| Total Liabilities | $67.1M |
| Equity | $30.6M |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Eton Pharmaceuticals Inc is a publicly traded company under the ticker symbol ETON on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)